# A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small

Source: https://onco.cc/trials/nct05785767/  
OnCo record `nct05785767` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of Fianlimab, Cemiplimab in non-small-cell lung cancer and small-cell lung cancer, run by Regeneron Pharmaceuticals, active and no longer recruiting.

## Summary

A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) is a phase 2/3 interventional study registered as NCT05785767 by Regeneron Pharmaceuticals, with 149 participants enrolled, started 2023-06-30 and due to reach its primary completion in 2027-09-28. Interventions recorded: fianlimab, cemiplimab, Placebo. Conditions listed: Advanced Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05785767
- Phase: 2/3
- Setting: A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody) in Combination With Cemiplimab (Anti-PD-1 Antibody) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 ≥50%
- Sponsor: Regeneron Pharmaceuticals
- Enrolled: 149

## Sources

- ClinicalTrials.gov NCT05785767: https://clinicaltrials.gov/study/NCT05785767

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Cemiplimab](https://onco.cc/drugs/cemiplimab/), [Fianlimab](https://onco.cc/drugs/fianlimab/)
- companies: [Regeneron](https://onco.cc/companies/regeneron/)

---
JSON: https://onco.cc/api/v1/entities/nct05785767.json